AstraZeneca vaccine: the risk of thrombosis is much higher for those who get sick with Covid

A (slightly) higher risk than the rest of the population. But in any case low and not comparable to what one could run by contracting Sars-CoV-2 infection and developing Covid-19 disease in a moderate or severe form.

The results of a study conducted on 280,000 Danish and Norwegian adults vaccinated (with the first dose) between February and March with the vaccine developed by AstraZeneca sound like confirmation.